Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Pastorelli

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Advances in Therapy|June 30, 2026
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE StudyGiuseppe Privitera, Flavia Palumbo, Fabio Salvatore Macaluso, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2026
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitisGiuseppe Privitera, Cristina Bezzio, Gisella Figlioli, et al.
The American Journal of Gastroenterology|February 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD StudyFranco Scaldaferri, Federica Di Vincenzo, Marina Aloi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Advances in Therapy|June 30, 2026
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE StudyGiuseppe Privitera, Flavia Palumbo, Fabio Salvatore Macaluso, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2026
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitisGiuseppe Privitera, Cristina Bezzio, Gisella Figlioli, et al.
The American Journal of Gastroenterology|February 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD StudyFranco Scaldaferri, Federica Di Vincenzo, Marina Aloi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Pageof 8